NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseGlobeNewsWire • 04/09/24
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of DirectorsBusiness Wire • 04/09/24
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerGlobeNewsWire • 04/01/24
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressGlobeNewsWire • 03/25/24
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDGlobeNewsWire • 03/12/24
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/28/24
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewsWire • 02/14/24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewsWire • 02/13/24
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/01/24
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial HighlightsGlobeNewsWire • 11/13/23
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial OfficerGlobeNewsWire • 10/23/23
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 MutationGlobeNewsWire • 09/21/23
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/20/23
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial OfficerGlobeNewsWire • 08/14/23
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsGlobeNewsWire • 08/07/23
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseGlobeNewsWire • 07/25/23
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary SharesGlobeNewsWire • 06/09/23
After Plunging -16.36% in 4 Weeks, Here's Why the Trend Might Reverse for NewAmsterdam Pharma Company N.V. (NAMS)Zacks Investment Research • 06/08/23
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary SharesGlobeNewsWire • 06/07/23